Guardion Health Sciences — Investor Presentation (November 2018)
32 slides from Guardion Health Sciences's investor presentation, Nov 21, 2018
Slide 1: Changing the Course of Eye Care
GUARDION HEALTH SCIENCES Changing the Course of Eye Care LUMEGAT VECTORVISION’ merpcatsF” , AcQviz Transcranial Doppler Solutions GlauteGetin (cular Blood Flow
Slide 2: Projected loss of sight in America
“It is projected that every four minutes, one American will experience partial or complete loss of sight. The need to confront preventable blindness has never been more urgent.” National Academics of Sciences, Engineering, and Medicine
Slide 3: Safe Harbor Statement
Changing the Course of Eye Care Safe Harbor Statement This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Such forward - looking statements are characterized by future or
Slide 4: Investment Highlights
Changing the Course of Eye Care Investment Highlights • Ophthalmic oriented life sciences company uniquely focused on the health of the retina, the density of the Macular Pigment (MP) and Ocular Blood Flow. • A Reduced or Depleted MP is a biomarker and major risk factor for multiple retinal conditio
Slide 5: About The Company
Changing the Course of Eye Care About The Company 5 • Guardion Health Sciences provides what we believe to be the first evidence - based protocol for prescription medical nutrition, combining highly accurate diagnostic devices with nutritional intervention using comprehensive medical foods, to chang
Slide 6: Early Detection, Intervention & Monitoring
Changing the Course of Eye Care Early Detection, Intervention & Monitoring 6 Mapcat SF MPOD VectorVision CSV - 1000 Contrast Sensitivity Lumega - Z Medical Food GlaucoCetin Medical Food Transcranial Doppler The GHS Portfolio AcQviz
Slide 7: The Relevance of the Macular Pigment
Changing the Course of Eye Care The Relevance of the Macular Pigment • A depleted macular protective pigment in the macula is a high risk factor and biomarker for retinal disease, retinal conditions and a biomarker for cognitive decline. 6 Increasing macular protective provides protection against re
Slide 8: The Relevance of the Macular Pigment
Changing the Course of Eye Care The Relevance of the Macular Pigment 8 • Macular Pigment is a modifiable high risk factor for Age - related Macular Degeneration 9 AMD • Significant improvements in contrast sensitivity, glare disability & photostress recovery can be achieved by increasing macular pig
Slide 9: How Macular Protective Pigment Protects the Retina
Changing the Course of Eye Care How Macular Protective Pigment Protects the Retina Depleted yellow macular protective layer puts retina at risk Restored macular protective layer shields retina from harmful light 9
Slide 10: Contrast Sensitivity
Changing the Course of Eye Care Contrast Sensitivity Contrast sensitivity measures how patients see in real world High Contrast Low Contrast AND 10 A depleted macular protective pigment greatly affects contrast sensitivity
Slide 11: Contrast Sensitivity (cont'd)
Changing the Course of Eye Care Contrast Sensitivity (cont’d) 11 Pilot acuity: poor measure of real world vision. Ginsberg, Evans et al 1985 Contrast Sensitivity Used by Military for Pilots Highway Accidents Accident drivers 6 times more likely to have poor contrast sensitivity! Owsley et al. 2001 A
Slide 12: What are Medical Foods?
Changing the Course of Eye Care 12 What are Medical Foods? A medical food is an official FDA product classification “which is formulated to be consumed or administered enterally (or orally) under medical supervision, and which is intended for the specific dietary management of a disease or condition
Slide 13: Medical Foods are a distinct FDA regulated category
13 Medical Foods are a distinct FDA regulated category, separate from dietary supplements and pharmaceuticals Lumega - Z has Medical Food status specifically for the purpose of replenishing and restoring a depleted macular protective pigment Supplements Vitamins Nutraceuticals Functional foods Presc
Slide 14: The Guardion Health Sciences Solution: MapCat-SF
Changing the Course of Eye Care The Guardion Health Sciences Solution 14 We believe our Mapcat - SF macular pigment optical density measurement device is what we believe to be the most effective tool available today for quickly and easily measuring the thickness of the macular pigment, called MPOD (
Slide 15: The Guardion Health Sciences Solution: VectorVision CSV-1000
Changing the Course of Eye Care The Guardion Health Sciences Solution 15 We believe that the VectorVision CSV - 1000 is the worldwide standard for contrast sensitivity, vision performance testing, and FDA clinical trials. It provides highly sensitive evaluation of vision changes for a variety of eye
Slide 16: Contrast Sensitivity VectorVision CSV-2000
Changing the Course of Eye Care 16 Contrast Sensitivity VectorVision CSV - 2000 2019 • The CSV - 2000 is the new digital version of the CSV - 1000 . • The recently issued patents Guardion has received for continuously calibrating the light source will be incorporated into the new CSV - 2000 . • Ther
Slide 17: AcQviz
Changing the Course of Eye Care AcQviz • Routine Clinic Vision Testing Has Long Lacked Standardization Even Though FDA and National Academy of Sciences Require Specific Light Levels • Lack of Standardization Has Held Back Incorporation of New Technology Also Does Not Allow Comparison of Surgical/Tre
Slide 18: The Guardion Health Sciences Solution: Lumega-Z
Changing the Course of Eye Care The Guardion Health Sciences Solution 18 We believe that Lumega - Z is the most comprehensive and targeted Medical Food nutritional intervention that can be prescribed by ocular health care professionals to address macular pigment depletion. We believe that it is the
Slide 19: The Guardion Health Sciences Solution: GlaucoCetin
Changing the Course of Eye Care The Guardion Health Sciences Solution 19 • Medical Food Specifically for Glaucoma patients • Reverses Mitochondrial Dysfunction • Improves blood flow in the ophthalmic artery • Clinically trial conducted under IRB/IND registered placebo controlled study at the New Yor
Slide 20: Transcranial Doppler (TCD) Ophthalmic Artery
Changing the Course of Eye Care Transcranial Doppler (TCD) 20 Ophthalmic Artery Dedicated to the pursuit of early predictors resulting in valuable therapeutic interventions. Published medical resources have indicated that TCD reveals a strong relationship between cerebral vessels, ocular circulation
Slide 21: Transcranial Doppler (TCD)
Changing the Course of Eye Care Transcranial Doppler (TCD) • In August 2018, Guardion created a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (“TDSI”), to further the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases and co
Slide 22: Evidence-based Protocol
Changing the Course of Eye Care Evidence - based Protocol 22 Depleted yellow macular protective layer puts retina at risk Restored macular protective layer shields retina from harmful light Low Contrast High Contrast • Restores the macular protective pigment (Bone et al. 2007) • Improves contrast se
Slide 23: Evidence-based Protocol
Changing the Course of Eye Care Evidence - based Protocol 23 Ultrasound Monitoring Technology Ocular Blood Flow • Reverses mitochondrial dysfunction ( Chrysostomou et al. 2013) • Improves ocular blood flow (Chung et al. 1999)
Slide 24: Growth Opportunities
Changing the Course of Eye Care Growth Opportunities 24 More than three million Americans are living with glaucoma, 2.7 million whom are aged 40 and older 19 22 million Glaucoma patients are Chinese patients which account for 25% of global Glaucoma patients 22 Due to an aging population, the AMD, Gl
Slide 25: Growth Opportunities
Changing the Course of Eye Care Growth Opportunities 25 AMD is the third leading cause of blindness in the world 24 More than 10 million Americans suffer from various forms of this life - limiting disease 26 Approximately 25 - 30 million people are affected worldwide by AMD 28 The incidence of AMD i
Slide 26: Projected Cases of AMD in US Population
Changing the Course of Eye Care Projected Cases of AMD in US Population 26 17.07 17.79 18.55 19.41 20.18 21.01 21.81 22.55 23.25 23.7 24.13 24.5 24.79 25.08 0 5 10 15 20 25 30 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 2038 2040 Data from: “Global prevalence of age - related macular
Slide 27: The Post-Cataract Market Opportunity
Changing the Course of Eye Care The Post - Cataract Market Opportunity • Patients are operated on earlier & younger. • After surgery, the long term damage from oxidative stress & high energy light exposure to the retina becomes more important to address. • Protecting the retina after surgery maintai
Slide 28: US Ophthalmology Practice Overview
Changing the Course of Eye Care US Ophthalmology Practice Overview 28 18,184 6,806 10,493 5,493 2,110 OD Individual OD Group MD Individual MD Group Retail 18,515 34,000 Ophthalmologists (MD) Optometrists (OD) Data from 2013 MarketScope Ophthalmic Diagnostic Equipment Market report & internal calcula
Slide 29: Management Team
Changing the Course of Eye Care Management Team Vincent J. Roth Esq., General Counsel Michael Favish President & CEO , Director Robert N. Weingarten Lead Director Mark Goldstone Director David W. Evans, PhD Director Chief Science Officer John Townsend Chief Accounting Officer 29
Slide 30: Science Advisory Board
The Guardion Science Advisory Board is a product development and research team of recognized experts in the fields of biochemistry, biophy si cs, and clinical nutrition. In addition to developing products based on scientific studies in the public domain, the Science Advisory Bo ard conducts and publ
Slide 31: Medical Advisory Board
Medical Advisory Board Robert Ritch, M.D. Dr. Robert Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Surgeon Director Emeritus and Chief of Glaucoma Services at the New York Eye & Ear Infirmary, New York City and Professor of Ophthalmology at The New York Medic
Slide 32: References
Changing the Course of Eye Care References 1. Henderson T., Weiss R., Evans D., Prospective Evaluation of Treatment for Early Macular Degeneration with a Micronized Lipid - Bas ed Liquid Carotenoid Formulation Vs AREDS2 Formula Tablet And Control Subjects, Guardion Health Sciences . 2. Igras , E.,.
Guardion Health Sciences — Investor Presentation (November 2018) on 6ix